Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lakewood-Amedex Biotherapeutics Inc. (LABT)

Lakewood-Amedex Biotherapeutics appoints Joseph Tucker, Ph.D., to its Board of Directors

Neutral Impact 3 of 5 leadership Written later

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) appointed Dr. Joseph Tucker to fill a vacancy on its Board effective April 24, 2026. Dr. Tucker is CEO and Director of Enveric Biosciences, and his compensation includes $6,000 per quarter in stock and 33,784 warrants exercisable at $10.00 per share, which may affect shareholders through dilution if exercised.

Key points

  • Board appointment effective April 24, 2026, with a term until the 2027 annual meeting
  • Compensation of $6,000 per quarter, payable in common stock, plus 33,784 warrants at a $10.00 exercise price with a ten-year term
  • Warrants vest in four tranches of 8,446 on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028
  • Dr. Tucker is CEO and Director of Enveric Biosciences (NASDAQ: ENVB) and joins the Finance, Audit, Risk, Compensation, and Governance committees

The filing

CompanyLakewood-Amedex Biotherapeutics Inc. (LABT)
Form8-K, current report
Filed with the SECApr 28, 2026, 4:15 PM ET
Accession number0001213900-26-048553

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.